Absentia Labs' Digital Liver Model has become the first AI drug development tool accepted into the FDA Qualification Program.

Absentia Labs' FDA qualification is a real benchmark for AI in drug development. For European CROs, generics, and small biotechs, this means regulatory bodies are actively engaging with AI tools. It clarifies that well-validated AI models can earn formal recognition, potentially streamlining preclinical stages and reducing trial timelines. This provides a tangible path for integrating AI into your R&D process with less regulatory risk.